180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake

Core Insights - 180 Life Sciences Corp. announced topline results from a clinical pharmacology study evaluating the uptake of cannabidiol (CBD) in solid formulations compared to the FDA-approved drug Epidiolex [1][2] - The study involved twelve volunteers and demonstrated that one of the solid formulations was absorbed faster and reached higher maximal levels than Epidiolex, while both formulations were well tolerated [2][3] - The development of solid formulations for CBD could enhance its clinical application for various indications, addressing the limitations of liquid formulations [4] Company Overview - 180 Life Sciences Corp. is a clinical stage biotechnology company focused on developing therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis [5] Clinical Study Details - The clinical trial was conducted in collaboration with Prof. Avi Domb and Prof. Elyad Davidson, comparing two solid formulations of CBD with Epidiolex [1][3] - The study results indicate that capsules made from one of the ProNanoLipospheres (PNL) formulations performed statistically better than Epidiolex in terms of absorption speed and maximal levels [3] - The other PNL formulation was found to be statistically equivalent to Epidiolex regarding absorption speed and maximal levels [3] Market Potential - The proprietary solid formulation for CBD delivery may provide medical professionals with expanded options for prescribing CBD in a high uptake pill format, potentially increasing market acceptance [4]